The trial enrolled 52 older adults with type 2 diabetes whose HbA1c—a laboratory measure of average blood glucose over roughly two to three months—was at or above 7.0 percent, a threshold indicating suboptimal control. Participants were randomly assigned either to an intervention group or to a control group receiving usual care. In the end, 45 participants completed the study, with 21 in the intervention arm and 24 in the control arm. The researchers measured HbA1c at baseline and again after 12 weeks using the AFINION 2 point-of-care analyzer, a device that delivers rapid results from a small blood sample, allowing outcomes to be assessed without sending samples to a central laboratory.

The intervention itself was designed around the Information–Motivation–Behavioral Skills model, a well-established framework in health psychology that holds that lasting behavior change requires three ingredients: accurate information, sufficient motivation, and the practical skills to act. In this trial, continuous glucose monitoring served as the information engine. Rather than handing participants raw sensor data and hoping for the best, the researchers integrated CGM-derived glucose patterns into individualized education sessions, collaborative goal setting, and repeated behavioral feedback. Each participant could see how their own daily choices—meals, activity, medication timing—translated into glucose curves, and then work with the program to set realistic, personal targets.

The results were striking. In the intervention group, HbA1c fell from an average of 8.16 percent at baseline to 7.49 percent at 12 weeks, a drop of 0.67 percentage points. Meanwhile, the control group moved in the wrong direction, with HbA1c rising from 7.47 percent to 7.68 percent. The difference in change between the two groups was statistically significant, with a reported test statistic of Z = -3.10 and p = 0.001. For context, clinical guidelines generally treat an HbA1c reduction of around 0.5 percentage points or more as clinically meaningful, because even modest reductions are associated with lower risks of long-term complications affecting the eyes, kidneys, nerves, and cardiovascular system.

Beyond blood sugar, the intervention produced broad secondary benefits. Compared with controls, participants in the intervention group showed significantly greater improvements in diabetes self-efficacy—the confidence to manage one’s own condition—with Z = -4.89 and p < 0.001, and in diabetes self-care activities, measured with a t statistic of 14.02 and p < 0.001. Body mass index also improved significantly between groups (t = -2.34, p = 0.012), as did subjective health status (Z = -3.10, p = 0.001) and health-related quality of life (Z = -3.27, p < 0.001). Waist circumference, another secondary outcome, was tracked alongside BMI as a marker of central adiposity, which is particularly relevant in metabolic disease.

The researchers also examined CGM-derived metrics within the intervention group, offering a window into how glucose patterns shifted over the program. Time in range—the percentage of readings between 70 and 180 mg/dL, widely regarded as the gold-standard CGM outcome—rose from a mean of 54.95 percent in participants’ first ambulatory glucose profile report to 61.76 percent in their last available report. Time above range at moderate levels (181–250 mg/dL) declined from 27.62 percent to 24.19 percent, and time above 250 mg/dL fell from 16.52 percent to 13.19 percent. Mean glucose dropped by roughly 10 mg/dL, from 183.52 to 173.62 mg/dL. However, the authors are careful to note that after Holm adjustment for multiple comparisons, these within-group CGM changes were not statistically significant, and the analyses were exploratory in nature, partly because report intervals varied between participants.

That statistical caution matters, and the authors are unusually transparent about the limits of their findings. Because CGM was delivered as part of a package that also included education, motivation, goal setting, and feedback, the trial cannot isolate the independent effect of the sensor itself. The measured benefits should be interpreted as the effect of the integrated program, not as proof that CGM alone changes outcomes in older adults. This distinction echoes a persistent theme in digital health research: wearable devices generate torrents of data, but data without interpretation, motivation, and skills training rarely translate into sustained behavior change. The IMB framework appears to have supplied the missing scaffolding.

The choice of study population is also significant. Older adults with type 2 diabetes are often underrepresented in diabetes technology trials, and clinicians have sometimes hesitated to prescribe CGM to this group, citing concerns about technological complexity, cost, and the ability of older patients to interpret the data. Yet older adults face the highest risks from both hyperglycemia and hypoglycemia, and individualized targets are central to geriatric diabetes care. By demonstrating that a structured program can help adults aged 65 and older not only tolerate but benefit from CGM-guided self-management, the study challenges assumptions about who can use diabetes technology effectively.

The trial was registered with the Clinical Research Information Service as KCT0009023, retrospectively registered on December 8, 2023, and approved by the Institutional Review Board of Jeonbuk National University, with written informed consent obtained from all participants. The work was funded by a National Research Foundation of Korea grant supported by the South Korean Ministry of Science and ICT. The authors declare no competing interests. Quality of life was assessed using the EQ-5D-5L instrument, scored with Korean valuation weights, adding a culturally anchored dimension to the health-status findings.

For a field racing to digitize diabetes care, the message of this trial is refreshingly practical: the sensor is only half the intervention. Continuous glucose monitoring gives patients and clinicians an unprecedented, near-real-time view of glucose dynamics, but the Korean study suggests that this view becomes genuinely transformative when it is embedded in a theory-driven program that builds information, motivation, and behavioral skills together. As health systems worldwide grapple with aging populations and rising diabetes prevalence, models that combine wearable technology with personalized human coaching may prove to be the most powerful prescription of all.

Subject of Research: A CGM-guided personalized self-management intervention for glycemic control and quality of life in older adults with type 2 diabetes

Article Title: CGM-guided personalized self-management intervention improves glycemic control and quality of life in older adults with type 2 diabetes: a randomized controlled trial

Article References: Cho, H., & Yang, Y. (2026). CGM-guided personalized self-management intervention improves glycemic control and quality of life in older adults with type 2 diabetes: a randomized controlled trial. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08348-z

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08348-z

Keywords: continuous glucose monitoring, type 2 diabetes, older adults, randomized controlled trial, HbA1c, self-management, IMB model, glycemic control, quality of life, diabetes self-efficacy, geriatrics, behavioral intervention